4000th Roche Cobas Amplicor Analyser rolls off production line
The 4000th COBAS AMPLICOR Analyser, has been manufactured by Roche Diagnostics and will be on display at the American Society for Microbiology General Meeting May 19-23 2002 in Salt Lake City.
The COBAS AMPLICOR Analyser is the first system to automate both the amplification and detection steps of the polymerase chain reaction (PCR) testing process. PCR is the leading nucleic acid amplification technology (NAT) in the world.
"We are extremely pleased on achieving this milestone of 4,000 COBAS AMPLICORs. This places the analyser in the ranks of the most placed diagnostic instruments for the clinical laboratory," says Heiner Dreismann, Ph.D., head of Roche Molecular Diagnostics. "In addition, we are continuing to develop innovative PCR solutions to provide our customers with the flexibility they need to perform molecular diagnostic tests with easy to use instrumentation, thus further improving their overall productivity," he adds.
The COBAS AMPLICOR Analyser was first launched in Europe in 1995 and in 1997 was the first NAT system to be cleared by the U.S. Food and Drug Administration. The analyser allows routine molecular based testing for infectious diseases such as human immunodeficiency virus (HIV-1)*, Chlamydia trachomatis & Neisseria gonorrhea, Mycobacterium tuberculosis*, cytomegalovirus (CMV)*, hepatitis B virus (HBV)* and hepatitis C virus (HCV). With the recent launch of Roche's latest automated platform, the COBAS AmpliPrep System that fully automates sample preparation of nucleic acids, Roche is now able to offer complete automation of molecular diagnostic tests.
The COBAS AMPLICOR Analyser has greatly helped to establish PCR as a practical and routine diagnostic tool for laboratory use around the world. The system has allowed clinical laboratories to efficiently handle their daily PCR testing workload, by making the testing process easier, and by helping to reduce technicians' "hands-on" time.
About Roche and Roche Molecular Diagnostics
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-oriented healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well being and quality of life. Roche's Diagnostics Division, the world leader in in- vitro diagnostics with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. Roche Molecular Diagnostics, a business area of Roche Diagnostics, has made the polymerase chain reaction (PCR) the leading nucleic acid amplification technology (NAT) in the world. PCR technology allows minute amounts of genetic material to be amplified into billions of copies in just a few hours, thereby facilitating detection of the DNA or RNA of pathogenic organisms even before antibodies to these organisms are formed.
# The COBAS AmpliPrep was launched in Europe in May 2001. This system is currently being used for research purposes only in the U.S.
* Available for research use only in the US.
Source: Roche Diagnostics View latest company information
Posted: April 25, 2002
[will open your email client]